InMed Pharmaceuticals (INM) Accumulated Expenses (2020 - 2026)

InMed Pharmaceuticals has reported Accumulated Expenses for 7 years, with the latest figure at $126767.0 in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Expenses fell 72.72% year-over-year to $126767.0; the trailing twelve-month figure through Mar 2026 stood at $126767.0 (down 72.72% YoY), and the FY2025 full-year result was $417927.0, down 14.41% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $126767.0, up from $65869.0 in the prior quarter.
• The five-year high for Accumulated Expenses was $839638.0 in Q2 2022, with the low at $65869.0 in Q4 2025.
• Historically, Accumulated Expenses has averaged $298992.8 across 5 years, with a median of $262017.0 in 2024.
• Annual changes were most pronounced in 2022 — Accumulated Expenses surged 394.95% — and 2025, when it tumbled 73.63%.
• InMed Pharmaceuticals' Accumulated Expenses stood at $839638.0 in 2022, then tumbled by 88.04% to $100446.0 in 2023, then soared by 148.67% to $249784.0 in 2024, then plunged by 73.63% to $65869.0 in 2025, then surged by 92.45% to $126767.0 in 2026.
• The last three Accumulated Expenses figures came in at $126767.0 (Q1 2026), $65869.0 (Q4 2025), and $274250.0 (Q3 2025), per Business Quant data.